EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination

Dille De Herdt iD, Evy Lefevere, Véronique Brouwers, Line Hartvig, Emiel Geeraerts, Cheng-Chih Hsiao, J Q Alida Chen iD, Rui Pinto, Guillaume Duvey, Stephen Burbidge, Anja Harmeier, Irene Knuesel iD

PLOS One · 27.07.2026 · 21 (7) · e0354525

DOI: 10.1371/journal.pone.0354525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 27.07.2026. Verfasst von Dille De Herdt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rewind Therapeutics NV, Leuven (Heverlee), Belgium. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Demyelinating Diseases. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rewind Therapeutics NV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelination, driven by differentiation of oligodendrocyte precursor cells, is critical for metabolic and structural support and efficient axonal signal transmission in neurons. Loss of myelin is a hallmark of multiple sclerosis and other devastating demyelinating disorders. As demyelination persists, neurons become increasingly vulnerable, leading to neurodegeneration and chronic disability. Restoring myelin through endogenous repair mechanisms offers a promising therapeutic approach to mitigate progressive neuronal loss. One key regulator of myelination is the G protein-coupled receptor 17, GPR17, whose chronic upregulation in oligodendrocyte precursor cells is commonly seen with myelin injury. In line with single-nucleus transcriptomic data showing predominant expression of GPR17 in committed oligodendrocyte precursor cells, our postmortem immunohistochemical analyses of MS patient tissue revealed a significant upregulation of GPR17 + /BCAS1 + oligodendrocyte precursor cells adjacent to and in demyelinated lesions. Importantly, remyelinated lesions lacked GPR17 immunoreactivity, consistent with a model in which sustained GPR17 expression is associated with demyelination and impaired oligodendrocyte precursor cell differentiation. To test the impact of pharmacological GPR17 inhibition on remyelination, we evaluated the effects of a novel, selective GPR17 antagonist in cuprizone-induced murine demyelination models. This toxin-induced approach has been widely used to study mechanisms of de- and remyelination, in the absence of the full inflammatory complexity of demyelinating diseases such as multiple sclerosis. We show that oral treatment results in robust functional recovery consistent with remyelination, as evidenced by improved spatial memory and recovery of visual evoked potential latency delays. GPR17 antagonism also accelerated structural remyelination in the corpus callosum and optic nerve. Together, these findings support a role for pharmacological GPR17 antagonism in promoting remyelination and highlight this G protein-coupled receptor as a promising therapeutic target for demyelinating disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledDemyelinating DiseasesAnimalsHumansMiceDisease Models, AnimalCuprizoneMyelin SheathRemyelinationRecovery of FunctionMultiple SclerosisCell DifferentiationMaleFemaleOligodendrocyte Precursor CellsNerve Tissue Proteins

Substanzen

Receptors, G-Protein-CoupledGPR17 protein, mouseCuprizoneGPR17 protein, humanNerve Tissue Proteins

Autor:innen und Institutionen

  • Rewind Therapeutics NV, Leuven (Heverlee), Belgium.
  • Excelra, Ghent, Belgium.
  • Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, Netherlands.
  • Department of Experimental Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, Netherlands.

ORCID-Profile: Dille De Herdt, J Q Alida Chen, Irene Knuesel

Förderung

  • Rewind Therapeutics NV

Zitieren

APA

De Herdt, D., Lefevere, E., Brouwers, V., Hartvig, L., Geeraerts, E., Hsiao, C. C., Chen, J. Q. A., Pinto, R., Duvey, G., Burbidge, S., Harmeier, A., & Knuesel, I. (2026). Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination. PLOS One, 21(7), e0354525. https://doi.org/10.1371/journal.pone.0354525

Vancouver

De Herdt D, Lefevere E, Brouwers V, Hartvig L, Geeraerts E, Hsiao CC, et al. Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination. PLOS One. 2026;21(7):e0354525. doi:10.1371/journal.pone.0354525

BibTeX
@article{DeHerdt2026,
  author = {De Herdt, Dille and Lefevere, Evy and Brouwers, Véronique and Hartvig, Line and Geeraerts, Emiel and Hsiao, Cheng-Chih and Chen, J Q Alida and Pinto, Rui and Duvey, Guillaume and Burbidge, Stephen and Harmeier, Anja and Knuesel, Irene},
  title = {Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0354525},
  doi = {10.1371/journal.pone.0354525}
}
Kostenlos starten →